A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN Smallpox Vaccine to ACAM2000 in 18-40 Year Old Healthy Vaccinia-naive Subjects
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Smallpox vaccine (Primary) ; ACAM 2000
- Indications Smallpox
- Focus Therapeutic Use
- Sponsors Bavarian Nordic
- 08 Nov 2017 According to a Bavarian Nordic media release, top-line results from this trial are expected in the first half of 2018.
- 20 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
- 20 Jul 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Aug 2017.